Literature DB >> 15688070

Psoriasis: emerging therapeutic strategies.

Alice B Gottlieb1.   

Abstract

Psoriasis is a chronic inflammatory skin disorder that is characterized by thickened, scaly plaques, and is estimated to affect approximately 1-3% of the Caucasian population. Traditional treatments, although effective in patients with limited disease, have numerous shortcomings, including inconvenience and toxicity. These drawbacks mean that many patients experience cycles of disease clearance, in which normal quality of life alternates with active disease and poor quality of life. However, as this review discusses, recent advances have highlighted the key role of the immune system in the pathogenesis of psoriasis, and have provided new defined targets for therapeutic intervention, offering hope for safe and effective psoriasis treatment.

Entities:  

Mesh:

Year:  2005        PMID: 15688070     DOI: 10.1038/nrd1607

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


  28 in total

1.  Serum neurotensin (NT) is increased in psoriasis and NT induces vascular endothelial growth factor release from human mast cells.

Authors:  M Vasiadi; A Therianou; K D Alysandratos; A Katsarou-Katsari; T Petrakopoulou; A Theoharides; E Papadavid; N Stavrianeas; C Antoniou; D Kalogeromitros; T C Theoharides
Journal:  Br J Dermatol       Date:  2012-05-14       Impact factor: 9.302

Review 2.  Immunopathogenesis of psoriasis.

Authors:  Brian J Nickoloff; Jian-Zhong Qin; Frank O Nestle
Journal:  Clin Rev Allergy Immunol       Date:  2007-10       Impact factor: 8.667

3.  Ustekinumab.

Authors:  Kristian Reich; Uma Yasothan; Peter Kirkpatrick
Journal:  Nat Rev Drug Discov       Date:  2009-05       Impact factor: 84.694

Review 4.  Unleashing the therapeutic potential of human kallikrein-related serine proteases.

Authors:  Ioannis Prassas; Azza Eissa; Gennadiy Poda; Eleftherios P Diamandis
Journal:  Nat Rev Drug Discov       Date:  2015-02-20       Impact factor: 84.694

Review 5.  CCR6 as a possible therapeutic target in psoriasis.

Authors:  Michael N Hedrick; Anke S Lonsdorf; Sam T Hwang; Joshua M Farber
Journal:  Expert Opin Ther Targets       Date:  2010-09       Impact factor: 6.902

6.  Cutting edge: NF-κB p65 and c-Rel control epidermal development and immune homeostasis in the skin.

Authors:  Yenkel Grinberg-Bleyer; Teruki Dainichi; Hyunju Oh; Nicole Heise; Ulf Klein; Roland M Schmid; Matthew S Hayden; Sankar Ghosh
Journal:  J Immunol       Date:  2015-02-13       Impact factor: 5.422

7.  Isoliquiritigenin prevents the progression of psoriasis-like symptoms by inhibiting NF-κB and proinflammatory cytokines.

Authors:  Yangping Wu; Xiangzheng Chen; Xiaojun Ge; Hongwei Xia; Yuxi Wang; Siyuan Su; Wenting Li; Tinghan Yang; Mingtian Wei; Hang Zhang; Lantu Gou; Jiong Li; Xian Jiang; Jinliang Yang
Journal:  J Mol Med (Berl)       Date:  2015-09-18       Impact factor: 4.599

8.  Development and validation of human psoriatic skin equivalents.

Authors:  Geuranne Tjabringa; Mieke Bergers; Desiree van Rens; Roelie de Boer; Evert Lamme; Joost Schalkwijk
Journal:  Am J Pathol       Date:  2008-07-31       Impact factor: 4.307

9.  Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis.

Authors:  P H Schafer; A Parton; A K Gandhi; L Capone; M Adams; L Wu; J B Bartlett; M A Loveland; A Gilhar; Y-F Cheung; G S Baillie; M D Houslay; H-W Man; G W Muller; D I Stirling
Journal:  Br J Pharmacol       Date:  2009-12-24       Impact factor: 8.739

Review 10.  Cytokines and cytokine profiles in human autoimmune diseases and animal models of autoimmunity.

Authors:  Manfred Kunz; Saleh M Ibrahim
Journal:  Mediators Inflamm       Date:  2009-10-26       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.